

CMS PROPOSES IMPROVED PAYMENT FOR CERAMENT® G IN THE U.S.

BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces that the U.S. Centers for Medicare & Medicaid Services (CMS) has published its proposed rule for the Medicare Inpatient Prospective Payment System (IPPS) for fiscal year 2027. The proposal includes changes that improves payments for the use of CERAMENT® G in the treatment of complex orthopedic infections, such as periprosthetic joint infection (PJI), fracture related infections, and diabetes related bone infection (diabetic foot).

In parallel, CMS proposes the introduction of more specific procedure and identification codes for CERAMENT G and CERAMENT® V, consistent with the company's submission.

CMS also proposes New Technology Add-on Payment (NTAP) reimbursement for CERAMENT V effective October 1, 2026, provided that the U.S. Food and Drug Administration (FDA) grants the company's De Novo application by April 30, 2026. If FDA approval is obtained at a later point in time, the company plans to submit a new NTAP application, with the potential for additional payment from October 1, 2027.

The company intends to submit additional clarifications to CMS during the ongoing 60-day public comment period. A final decision from CMS is expected in late summer 2026.

For more information contact:

BONESUPPORT AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
14 April 2026 16:48:00 CEST



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

[CMS PROPOSES IMPROVED PAYMENT FOR CERAMENT® G IN THE U.S.](#)